Sensus Healthcare

Sensus Healthcare is a commercial-stage medical device company with a mission to democratize access to non-invasive radiation therapy for common skin conditions. Its core achievement is the development and FDA clearance of the SRT-100 platform, which has established a new office-based treatment paradigm for non-melanoma skin cancer and keloids. The company's strategy focuses on expanding its installed base through direct sales, enhancing its technology with image-guidance (SRT-100 Vision), and leveraging strong clinical data and favorable reimbursement to drive adoption among dermatologists and radiation oncologists.

Proprietary Superficial Radiotherapy (SRT) platform utilizing low-energy X-rays to non-invasively treat non-melanoma skin cancers and keloids, with advanced iterations featuring integrated high-frequency ultrasound for image guidance.

Sensus competes primarily against surgical standards of care (Mohs, excision) and other superficial radiation devices. Its differentiation lies in its dedicated office-based design, integrated ultrasound guidance for the SRT-100 Vision, strong clinical data in keloid prevention, and an established reimbursement pathway targeting dermatologists and plastic surgeons.